However, in contrast to trastuzumab, which is licensed for the treatment of human epidermal growth factor receptor 2 positive breast cancer OCR is approved for the treatment of patients with relapsing or primary progressive form of multiple sclerosis [20,21,22,23]. This evidence concerns the gene ERBB2 and breast cancer.